Congratulations! FAB Supports Approval of ROS1 Inhibitor Taletrectinib for the Treatment of Non-Small Cell Lung Cancer!
On December 20, 2024, the official website of China's National Medical Products Administration (NMPA) announced that the marketing application for taletrectinib adipate capsul...